Monday, February 13, 2012 3:20:23 PM
Recent ME News
- Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:06:05 PM
- 23andMe to Report Q4 and Full Year FY2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:50:07 PM
- Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case • Business Wire • 04/30/2024 03:00:00 PM
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:05:00 PM
- 23andMe announces CEO’s intention to pursue a potential take-private • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 04/05/2024 08:05:00 PM
- 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- 23andMe Launches New Genetic Reports on Common Forms of Cancer • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:36:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:07:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:03:56 PM
- 23andMe Reports Third Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 02/07/2024 09:01:00 PM
- Moneta Gold and Nighthawk Gold Complete At-Market Merger to form STLLR Gold Inc. • Business Wire • 02/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 12:50:09 PM
- 23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay • GlobeNewswire Inc. • 01/31/2024 03:12:36 AM
- Nighthawk Gold Obtains Final Court Order for the Proposed Arrangement • Business Wire • 01/30/2024 10:00:00 PM
- 23andMe to Report FY2024 Third Quarter Financial Results • GlobeNewswire Inc. • 01/24/2024 09:05:00 PM
- Moneta Gold and Nighthawk Gold Announce the Proposed Directors for the MergeCo Board • Business Wire • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:45:21 PM
- 23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts • GlobeNewswire Inc. • 12/19/2023 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/01/2023 09:06:04 PM
- Nighthawk and Moneta Announce At-Market Merger to Create a Leading Canadian Gold Development Company • Business Wire • 11/28/2023 12:15:00 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM